Collapse all
The Business Model Canvas reveals a high-value, high-risk clinical service that leverages a significant efficacy gap in traditional AUD treatments. Success depends on navigating a complex regulatory landscape and maintaining a high-touch, specialized clinical environment to mitigate safety risks.
4 FDA/State Regulators Essential for IND protocols or Measure 109 licensing to legally administer Schedule I substances. Specialized Pharmacies Suppliers of pharmaceutical-grade psilocybin to ensure dosing consistency (25–40 mg/70 kg). Addiction Networks Partnerships with organizations like Hazelden Betty Ford for patient referrals and clinical validation. Psychological Boards Certification bodies to ensure therapists are trained in the specific manualized CBT and motivational enhancement protocols. 4 Clinical Screening Rigorous psychiatric vetting to exclude patients with contraindications and prevent adverse events like automutilation. Supervised Dosing Managing two high-dose psilocybin sessions in a supportive, safe environment to prevent 'bad trips'. Integration Therapy Executing the 12-week manualized psychotherapy combining CBT and motivational enhancement. Outcome Monitoring Tracking heavy drinking days via timeline followback interviews over a 32-week period. 4 Licensed Clinical Space Specialized outpatient facilities designed for long-duration, supervised psychedelic experiences. Trained Psychotherapists Clinicians expert in both addiction medicine and psychedelic-assisted integration. Clinical Protocols The specific 12-week manualized therapy and dosing schedule proven to reduce heavy drinking days. Regulatory Permits FDA IND approvals or state-level service center licenses required for legal operation. 4 Superior Efficacy Significant reduction in heavy drinking days (from 23.6% to 9.7%) compared to traditional pharmacotherapies. Treatment for Resistance A viable alternative for high-income professionals who have failed naltrexone, acamprosate, or disulfiram. Short-Term Intensity A concentrated 12-week active treatment phase rather than indefinite daily medication. Safety-First Delivery Professional supervision that eliminates the risks associated with unsupervised psychedelic use. 3 High-Touch Clinical Care Intensive, one-on-one support during dosing and integration to ensure psychological safety. Long-term Monitoring Maintaining a relationship through 32 weeks of follow-up to track sobriety and prevent relapse. Trust-Based Screening Establishing a rigorous intake process to ensure patient-treatment fit and safety. 3 Specialist Referrals Direct pipelines from addiction medicine clinics and psychiatric practitioners. Clinical Research Sites Recruiting patients through FDA-approved research trials and academic partnerships. Private Healthcare Networks Targeting high-income professional networks through executive health programs. 3 Treatment-Resistant AUD Patients Adults with alcohol use disorder who have not responded to standard pharmacotherapy. High-Income Professionals Individuals capable of paying out-of-pocket for high-intensity, private outpatient care. Clinical Research Participants Patients seeking cutting-edge interventions through NIAAA or other research-backed programs. 4 Specialized Labor High costs for dual-trained clinicians (psychiatrists and therapists) required for supervision. Facility Overhead Costs of maintaining a licensed, safe, and supportive clinical environment for day-long sessions. Regulatory Compliance Legal and administrative costs associated with maintaining IND protocols or state licenses. Pharmaceutical Sourcing Procurement of standardized, high-purity psilocybin. 3 Package-Based Pricing A flat fee for the full 12-week program, including preparation, two dosing days, and integration. Follow-up Care Fees Subscription or per-session fees for the 32-week monitoring and maintenance phase. Research Grants Funding from organizations like the NIAAA for conducting clinical trials on AUD. The idea is concrete enough to define a specific high-income target customer and a structured service delivery model. · Generated 2026-09-11 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated